AlphAIAlphAI — Financial news for AI agents
StockOTC · US · USDHealthcare · Medical Devices

$ZOMDF

Zomedica Corp.

Zomedica is an animal health company that develops and markets diagnostic and therapeutic products for veterinarians treating companion animals, including dogs, cats and horses. Its six product lines include TRUFORMA point-of-care diagnostic instruments and assays, the TRUVIEW digital microscopy platform, VETGuardian remote vital-signs monitoring systems, PulseVet shockwave therapy devices, Assisi targeted pulsed electromagnetic field products, and VETIGEL hemostatic gel. The company also provides development services beyond animal health. Zomedica sells directly to veterinary professionals, through online orders and retail channels, and through third-party distributors. It earns money from products and related consumables, subscriptions for TRUVIEW systems, and fees for remote pathology interpretations. Its U.S. sales force markets products domestically, while distributors serve international markets for some product lines. Zomedica is headquartered in Ann Arbor, Michigan.

Price · $ZOMDFvia TradingView
AI sentiment · 7d3 articles
OCT 30net (bullish − bearish)NOV 5
Bullish
3
Neutral
0
Bearish
0
Insider · 30dAll trades →

No SEC Form 4 filings for $ZOMDF in the last 30 days.

See all $ZOMDF insider activity →
Top stories · $ZOMDFMore →
·SEC EDGAR 8-KMed

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity Zomedica surpasses $9 million in quarterly revenue for the second quarter in a row while extending its record of consecutive ye

·stocktitan.net

An animal health company cut its quarterly loss 48% to $3.2 million

Zomedica Corp. (ZOMDF) reported a 48% reduction in its quarterly loss to $3.2 million, with record revenue of $9.9 million, up 22% year-over-year. The company saw growth in diagnostics (up 113%) and therapeutic devices (up 7%), while operating expenses decreased 21%. Cash burn improved by 32%, and liquidity stood at $40.9 million as of September 30, 2026, according to the company.

·finanznachrichten.de

Zomedica Corp.: Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

Zomedica Corp. (OTCQB:ZOMDF) reported record Q2 2026 revenue of $9.5 million, up 37% year over year, with gross margin of 64%. Operating expenses fell 20% to $10.1 million and cash burn improved 38% to $3.4 million. The company said liquidity totaled $44.1 million and cited growth in Diagnostics, Therapeutic Devices, and Development Services.

ZOMDF sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ZOMDF (Zomedica Corp.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.

Recent ZOMDF coverage spans earnings, corporate actions and financial news.

What's driving ZOMDF

  • Earnings beat on revenue growth and cash burn improvement may lift the stock.

    SEC EDGAR 8-K · Nov 4, 2026

  • Loss reduction and revenue growth may lift the stock.

    stocktitan.net · Nov 4, 2026

  • The print shows accelerating top-line growth, improved cash burn, and stronger liquidity, which can reduce near-term financing risk.

    finanznachrichten.de · Aug 5, 2026

  • Record quarterly revenue growth and improved cash burn suggest improving operating leverage, but the OTC microcap context implies higher execution and liquidity risk.

    SEC EDGAR 8-K · Aug 5, 2026

  • The 8-K confirms governance outcomes: directors and auditors were approved, but executive compensation received a majority “against,” which can affect investor sentiment and future proxy negotiations.

    SEC EDGAR 8-K · Jun 11, 2026

AlphAI scores every news story that mentions ZOMDF with an AI model for sentiment and relevance, and aggregates insider trades from Zomedica Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZOMDF

Score
$ZOMDFMedSEC EDGAR 8-K

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity Zomedica surpasses $9 million in quarterly revenue for the second quarter in a row while extending its record of consecutive ye

$ZOMDFMedAI 9/10finanznachrichten.de

Zomedica Corp.: Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

Zomedica Corp. (OTCQB:ZOMDF) reported record Q2 2026 revenue of $9.5 million, up 37% year over year, with gross margin of 64%. Operating expenses fell 20% to $10.1 million and cash burn improved 38% to $3.4 million. The company said liquidity totaled $44.1 million and cited growth in Diagnostics, Therapeutic Devices, and Development Services.

$ZOMDFMedSEC EDGAR 8-K

Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity Zomedica surpasses $9 million in second quarter revenue for the first time while extending its record of consecutive year-ov

$ZOMDFLowSEC EDGAR 8-K

Zomedica Corp. (ZOMDF): Submission of Matters to a Vote of Security Holders

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zom_8k.htm 0001684144 false 0001684144 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da

Related tickers

More in Medical Devices